Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $28

Benzinga · 1d ago
Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $58 to $28.